ESG Telegraph
  • Home
  • Latest News
  • Environment
  • Companies
  • Investors
  • Governance
  • Markets
  • Social
  • Regulators
  • Sustainable Finance
Featured Posts
    • Latest News
    Small businesses count cost of Apple’s privacy changes
    • August 9, 2022
    • Companies
    Bayern Munich targets US fans to close financial gap with Premier League
    • August 9, 2022
    • Markets
    Sweden’s junior market becomes Europe’s hottest for growth stocks
    • August 9, 2022
    • Latest News
    Tibetan cities locked down over first Covid outbreak in two years
    • August 9, 2022
    • Companies
    London’s ‘magic circle’ law firms make renewed bid to crack US
    • August 9, 2022
Featured Categories
Belarussia
View Posts
Companies
View Posts
Energy
View Posts
Environment
View Posts
Food
View Posts
Governance
View Posts
Health
View Posts
Investors
View Posts
Latest News
View Posts
Markets
View Posts
Potash
View Posts
Regulators
View Posts
Russsia
View Posts
Social
View Posts
Supply Chain
View Posts
Sustainable Finance
View Posts
Technology
View Posts
Uncategorized
View Posts
ESG Telegraph ESG Telegraph
7K
9K
4K
1K
ESG Telegraph ESG Telegraph
  • Home
  • Latest News
  • Environment
  • Companies
  • Investors
  • Governance
  • Markets
  • Social
  • Regulators
  • Sustainable Finance
  • Companies

Covid vaccine pushes AstraZeneca to record revenues

  • February 10, 2022
  • Staff
Total
0
Shares
0
0
0

AstraZeneca has reported a record quarter for revenues, including $1.8bn from its Covid-19 vaccine and sales from its $39bn acquisition of rare disease company Alexion.

Total revenue at the UK drugmaker soared 63 per cent year on year to $12bn in the fourth quarter after the effect of currency moves were stripped out — higher than the consensus forecast for $11bn. Two cancer drugs — Tagrisso and Lynparza — and Soliris for a rare disease each generated more than $1bn in the three-month period.

Core earnings per share rose 74 per cent to $1.67, above the average analysts’ estimate of 73 cents.

The company raised its dividend for the first time in a decade, with a total 2021 dividend of $2.87.

Pascal Soriot, AstraZeneca’s chief executive, said the company had “industry-leading research and development productivity”, with five new medicines becoming blockbusters — producing more than $1bn revenue a year — in 2021.

“We also delivered on our promise of broad and equitable access to our Covid-19 vaccine with 2.5bn doses released for supply around the world,” he added.

AstraZeneca made its first sales of its Covid-19 vaccine on a for-profit basis in the quarter but did not give detail of the revenue generated from the new contracts. The shot is significantly cheaper than the mRNA jab from BioNTech and Pfizer. Pfizer reported $12.5bn of sales of its Covid-19 vaccine in the fourth quarter.

AstraZeneca forecasts a high teens percentage increase in total revenue in 2022, with currency movements stripped out, and a mid-to-high twenties percentage rise in core earnings per share.

Soriot took the top job at AstraZeneca almost 10 years ago, focusing on innovation and investment in R&D. The company now has 13 blockbusters, five of which have multibillion-dollar sales. In 2021, AstraZeneca had 22 regulatory approvals and authorisations, and 14 positive late-stage trial results for nine medicines.

In 2021 it reported total revenue of $37bn, up 38 per cent year on year at constant exchange rates, of which $4bn was from the Covid-19 vaccine developed in partnership with Oxford university. The company experienced double-digit growth in all of its major regions, despite pressure on prices in China.

AstraZeneca closed its deal to buy Alexion in July 2021. The acquisition brought a pipeline of drugs for rare diseases. Rare disease treatments contributed 8 per cent of revenue in 2021.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
You May Also Like
Read More
  • Companies

Bayern Munich targets US fans to close financial gap with Premier League

  • Staff
  • August 9, 2022
Read More
  • Companies

London’s ‘magic circle’ law firms make renewed bid to crack US

  • Staff
  • August 9, 2022
Read More
  • Companies

FirstFT: Rishi Sunak promises to ease cost of living crisis

  • Staff
  • August 9, 2022
Read More
  • Companies

First single-bond ETFs look set to revolutionise access to Treasuries

  • Staff
  • August 9, 2022
Read More
  • Companies

We must regulate the exploitation of limited resources in space

  • Staff
  • August 9, 2022
Read More
  • Companies

Toyota unit Hino admits falsifying engine data for nearly 20 years

  • Staff
  • August 9, 2022
Read More
  • Companies

ANZ once more bets on an acquisition to spur growth

  • Staff
  • August 9, 2022
Read More
  • Companies

UK retail sales growth fails to keep pace with soaring inflation

  • Staff
  • August 9, 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Featured Posts
  • 1
    Small businesses count cost of Apple’s privacy changes
    • August 9, 2022
  • 2
    Bayern Munich targets US fans to close financial gap with Premier League
    • August 9, 2022
  • 3
    Sweden’s junior market becomes Europe’s hottest for growth stocks
    • August 9, 2022
  • 4
    Tibetan cities locked down over first Covid outbreak in two years
    • August 9, 2022
  • 5
    London’s ‘magic circle’ law firms make renewed bid to crack US
    • August 9, 2022
Recent Posts
  • Fed help isn’t coming | Financial Times
    • August 9, 2022
  • News Corp profits almost double as subscriptions drive post-pandemic recovery
    • August 9, 2022
  • FirstFT: Rishi Sunak promises to ease cost of living crisis
    • August 9, 2022

Sign Up for Our Newsletters

Subscribe now to our newsletter

ESG Telegraph
  • Home
  • Privacy Policy
  • Guest Post
  • Contact

Input your search keywords and press Enter.